Garuda Therapeutics
Garuda Therapeutics was a clinical-stage biotechnology company founded in 2021 by Sean Morrison and David Scadden and headquartered in Massachusetts (Cambridge, later Natick), developing off-the-shelf, self-renewing, HLA-compatible, transgene-free hematopoietic (blood) stem cell therapies intended to remove the dependency on a matched donor or on patient cells in the treatment of hematologic malignancies, sickle cell disease, beta-thalassemia and bone marrow failure. It raised roughly $184M across a $72M Series A and a $50M Series A-1 closed in March 2025, backed by OrbiMed Advisors, Northpond Ventures, Cormorant Asset Management and Kyowa Kirin. It is a therapeutics developer, not a software company: it never published an API, SDK, developer portal or machine-readable specification, and its website garudatx.com no longer serves company content and now resolves to a GoDaddy parking lander.
Garuda Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, Cell Therapy, and Stem Cells.
Kin Score
Resources
Other 1
Properties that don't map to a standard resource type